Drugs / Factor VIII Inhibitor Bypassing Activity
Factor VIII Inhibitor Bypassing Activity
also known as
FEIBA · activated prothrombin complex concentrate · aPCC · Factor Eight Inhibitor Bypassing Activity
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT04563520 | Jun 2026 → Mar 2027 expected | hemophilia A | Emory University | Recruiting | No outcome recorded |
| Phase 3 | NCT02764489 | Feb 2019 → Dec 2021 | hemophilia | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04205175 | Jul 2020 → Oct 2022 overdue | hemophilia A | Children's Hospital Los Angeles | Active not recruiting | No outcome recorded |
| Phase 4 | NCT00284193 | Jan 2005 → Nov 2008 | hemophilia A | Sheba Medical Center | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00166309 | Jul 2000 → Jun 2005 | severe hemophilia A | Skane University Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT05662319 Background | Feb 2023 → Mar 2027 expected | hemophilia | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00851721 Comparator | Mar 2009 → Oct 2012 | hemophilia A, hemophilia B | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01800435 Comparator | Oct 2011 → Oct 2012 | hemophilia A | Oslo University Hospital | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | factor VIII inhibitor-bypassing activity | “FEIBA (factor VIII inhibitor-bypassing activity), an activated prothrombin complex concentrate (aPCC), and NovoSeven, recombinant factor VIIa (rFVIIa), are used as hemostatic...” PMID 16990605 ↗ Sep 2006 |
| Known as | activated prothrombin complex concentrate | “bypassing agents such as activated prothrombin complex concentrate (aPCC/Feiba)” NCT04205175 ↗ |
| Known as | aPCC | “bypassing agents such as activated prothrombin complex concentrate (aPCC/Feiba)” NCT04205175 ↗ |
| Known as | Factor Eight Inhibitor Bypassing Activity | “Treatment with the nanofiltered anti-inhibitor coagulant complex, Factor Eight Inhibitor Bypassing Activity (FEIBA NF), is a key therapeutic option for controlling acute...” PMID 23910578 ↗ Aug 2013 |
| Known as | FEIBA | “A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab” NCT04205175 ↗6“Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o” NCT01800435 ↗ |
| Modality | Protein / enzyme biologic | “Activated Prothrombin Complex Concentrates (APCC, eg. FEIBA)” NCT00284193 ↗ |
| Route | Intravenous | “Feiba 75 IU/kg i.v” NCT01800435 ↗ |